

**5-phospho-alpha-D-ribose 1-diphosphate
(PRPP) + H₂O + L-glutamine \rightleftharpoons 5-phos-
phoribosylamine + L-glutamate + pyropho-
sphate**

D'Eustachio, P., Jassal, B.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](#). For more information see our [license](#).

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 73


This document contains 1 reaction ([see Table of Contents](#))

5-phospho-alpha-D-ribose 1-diphosphate (PRPP) + H₂O + L-glutamine <=> 5-phosphoribosylamine + L-glutamate + pyrophosphate ↗

Stable identifier: R-HSA-73815

Type: transition

Compartments: cytosol



Cytosolic PPAT (phosphoribosyl pyrophosphate amidotransferase) catalyzes the reaction of 5-phospho-alpha-D-ribose 1-diphosphate (PRPP), water, and L-glutamine to form 5-phosphoribosylamine, L-glutamate, and pyrophosphate. This event is the committed step in de novo purine synthesis. The reaction itself is reversible, but it is pulled strongly in the direction of 5'-phosphoribosylamine synthesis by the irreversible hydrolysis of the pyrophosphate that is also formed in the reaction. Fluorescence microscopy studies of cultured human cells have shown that PPAT is cytosolic and suggest that it may co-localize with other enzymes of de novo IMP biosynthesis under some metabolic conditions (An et al. 2008). The PPAT enzyme is inferred to be an iron-sulfur protein, like its well-characterized *B. subtilis* homologue, because incubation of purified enzyme with molecular oxygen or chelating agents inactivates it, and activity can be restored by incubation with ferrous iron and inorganic sulfide. The stoichiometry of the iron-sulfur moiety and its role in enzyme activity remain unknown (Itakura and Holmes 1979). The fully active form of the enzyme is a dimer, which can associate further to form a tetramer with sharply reduced activity (Holmes et al. 1973b; Iwahana et al. 1993). Interaction of the enzyme with inosine 5'-monophosphate (IMP), guanosine 5'-monophosphate (GMP), and adenosine 5'-monophosphate (AMP), end products of de novo purine biosynthesis, favors tetramer formation, while interaction with 5-phospho-alpha-D-ribose 1-diphosphate (PRPP), a required substrate, favors formation of the active dimer. Kinetic studies suggest that the enzyme's binding site for GMP and IMP is separate from its AMP binding site (Holmes et al. 1973a).

Literature references

- Itakura, M., Holmes, EW. (1979). Human amidophosphoribosyltransferase. An oxygen-sensitive iron-sulfur protein. *J Biol Chem*, 254, 333-338. ↗
- Iwahana, H., Oka, J., Mizusawa, N., Kudo, E., Ii, S., Yoshimoto, K. et al. (1993). Molecular cloning of human amidophosphoribosyltransferase. *Biochem Biophys Res Commun*, 190, 192-200. ↗

An, S., Kumar, R., Sheets, ED., Benkovic, SJ. (2008). Reversible compartmentalization of de novo purine biosynthetic complexes in living cells. *Science*, 320, 103-6. [↗](#)

Holmes, EW., Wyngaarden, JB., Kelley, WN. (1973). Human glutamine phosphoribosylpyrophosphate amidotransferase. Two molecular forms interconvertible by purine ribonucleotides and phosphoribosylpyrophosphate. *J Biol Chem*, 248, 6035-6040. [↗](#)

Holmes, EW., McDonald, JA., McCord, JM., Wyngaarden, JB., Kelley, WN. (1973). Human glutamine phosphoribosylpyrophosphate amidotransferase. Kinetic and regulatory properties. *J Biol Chem*, 248, 144-150. [↗](#)

Editions

2003-06-26	Authored	Jassal, B.
2010-02-06	Revised	D'Eustachio, P.
2020-05-27	Edited	Jassal, B., D'Eustachio, P.